Warning! GuruFocus detected
1 Severe warning sign
with LPTX.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Leap Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US52187K1016
Description
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 177.63 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 26.6 | |||||
| 3-Year EPS without NRI Growth Rate | 27 | |||||
| 3-Year FCF Growth Rate | 26.8 | |||||
| 3-Year Book Growth Rate | -57.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 24.56 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.51 | |||||
| 9-Day RSI | 39.57 | |||||
| 14-Day RSI | 33.11 | |||||
| 3-1 Month Momentum % | -85.61 | |||||
| 6-1 Month Momentum % | -81.09 | |||||
| 12-1 Month Momentum % | -82.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.41 | |||||
| Quick Ratio | 3.41 | |||||
| Cash Ratio | 3.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -63.1 | |||||
| Shareholder Yield % | -310.58 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -131.28 | |||||
| ROA % | -103.49 | |||||
| ROIC % | -3951.54 | |||||
| 3-Year ROIIC % | 25839.51 | |||||
| ROC (Joel Greenblatt) % | -18000.26 | |||||
| ROCE % | -136.04 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.33 | |||||
| Price-to-Tangible-Book | 0.33 | |||||
| EV-to-EBIT | 0.47 | |||||
| EV-to-EBITDA | 0.47 | |||||
| EV-to-FCF | 0.55 | |||||
| Price-to-Net-Current-Asset-Value | 0.34 | |||||
| Price-to-Net-Cash | 0.35 | |||||
| Earnings Yield (Greenblatt) % | 212.77 | |||||
| FCF Yield % | -485.11 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LPTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Leap Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.84 | ||
| Beta | 0.64 | ||
| 3-Year Sharpe Ratio | -0.22 | ||
| 3-Year Sortino Ratio | -0.35 | ||
| Volatility % | 115.27 | ||
| 14-Day RSI | 33.11 | ||
| 14-Day ATR ($) | 0.06483 | ||
| 20-Day SMA ($) | 0.390825 | ||
| 12-1 Month Momentum % | -82.38 | ||
| 52-Week Range ($) | 0.28 - 4.79 | ||
| Shares Outstanding (Mil) | 41.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Leap Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Leap Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Leap Therapeutics Inc Frequently Asked Questions
What is Leap Therapeutics Inc(LPTX)'s stock price today?
The current price of LPTX is $0.30. The 52 week high of LPTX is $4.79 and 52 week low is $0.28.
When is next earnings date of Leap Therapeutics Inc(LPTX)?
The next earnings date of Leap Therapeutics Inc(LPTX) is 2025-05-13 Est..
Does Leap Therapeutics Inc(LPTX) pay dividends? If so, how much?
Leap Therapeutics Inc(LPTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers